Sign In
6 Mar 2018 16:33
REDX PHARMA PLC
("Redx" or "the Company")
Result of Annual General Meeting
Alderley Park, March 6 2018 - Redx (AIM: REDX), the drug discovery and development company, announces that all resolutions at the Group's Annual General Meeting, held today, were duly passed.
For further information, please contact:
Redx Pharma Plc | T: +44 1625 469 918 |
Iain Ross, Executive Chairman |
|
Cantor Fitzgerald Europe (Nominated Advisor & Broker) | T: +44 20 7894 7000 |
Phil Davies |
|
|
|
WG Partners LLP (Joint Broker) | T: +44 20 3705 9330 |
Claes Spång/ Chris Lee/ David Wilson |
|
|
|
FTI Consulting | T: +44 20 3727 1000 |
Simon Conway/Stephanie Cuthbert |
|
About Redx Pharma Plc
Redx is a UK biotechnology company whose shares are traded on AIM (AIM:REDX). Redx is focused on creating and developing first, or potentially best in class drugs, in specific areas of cancer and fibrosis that address significant unmet medical need. Redx has an in-house discovery team with proven world-class chemistry capabilities.
Follow the stocks
